COMPANY PROFILE / NANOTECHNOLOGY
Acuitas Therapeutics
A privately held company with no drugs of its own that supplies LNP lipids and formulations to partners
Acuitas Therapeutics is a privately held biotechnology company based in Vancouver, Canada. Its website describes it as a technology-platform company that develops no drugs of its own and instead provides lipid nanoparticle (LNP) technology for delivering nucleic acid medicines to partners such as pharmaceutical and biotech companies, universities, foundations and NGOs. It says its LNP technology is used in two approved products, ONPATTRO and COMIRNATY, and BioNTech's Form 20-F says it took a non-exclusive license from Acuitas in April 2020.
Because Acuitas is not listed, its financials and headcount are not published. Beyond the company's own website, press releases and corporate presentation, this article draws on disclosures by BioNTech, Alnylam and Arbutus, court documents and regulators' documents to sort out what could and could not be confirmed. The patent disputes with Arbutus and Genevant are treated neutrally, as each party's position, and this article does not judge whether any patent is valid or infringed.
- At a glance: Acuitas and its place in nanotechnology
- Logo and naming
- Where the company sits in nanotechnology
- Company scale
- Resources committed to nanotechnology
- Track record
- Plans
- What the company is aiming for in nanotechnology
- Partnership map for nanotechnology
- Technologies, products and services
- Risks
- Glossary
- References
- Claim-to-source audit
1. At a glance: Acuitas and its place in nanotechnology
Agronomy Road6190 Agronomy Road, Suite 205 (website). Founders: Thomas Madden, Michael Hope and Pieter Cullis
(LNP technology provider)Has no drugs of its own; supports partners' development
ionizable and PEG-lipidsDelivery of mRNA, siRNA, guide RNA, DNA and others (company's description)
ONPATTRO and COMIRNATYBioNTech records a non-exclusive license from it; Arbutus also calls the ONPATTRO LNP its technology
Acuitas is not a drug maker but a company that provides LNP components (lipids) and recipes Sourced. Its website and corporate presentation state that it has no drug development programs of its own and works in collaboration with partners. Designing and supplying the particle that wraps an mRNA vaccine or siRNA drug is what it does.
Its involvement in approved products rests mostly on company claims, and the primary sources that confirm it are partial. BioNTech's Form 20-F says it took a non-exclusive license from Acuitas, but who manufactures the lipids in the Pfizer/BioNTech vaccine is not stated in the materials read for this article Not yet confirmed. Arbutus and Genevant, meanwhile, have sued Pfizer/BioNTech claiming that the same COMIRNATY LNP infringes their patents, and Acuitas sits at the edge of that dispute (no ruling has been made).
2. Logo and naming
The logo is the logo image published on the company's official website (acuitastx.com), the words ACUITAS THERAPEUTICS with a round mark, with only the surrounding margin trimmed. It has not been recreated with generated images.
Naming: the company is Acuitas Therapeutics Inc. Alnylam's 10-K exhibit index records it as "Acuitas Therapeutics Inc. (formerly AlCana Technologies, Inc.)." The website explains that "Acuitas" means "insight, perception and sharpness." ALC-315 is a name the corporate presentation says is a registered trademark at the US Patent and Trademark Office, not a company name.
Official site: https://acuitastx.com/3. Where the company sits in nanotechnology
Acuitas's main type is nanomedicine, with no secondary type. It holds LNP patents and offers everything from designing new lipids to formulation, analytics, preclinical work and manufacturing technology transfer. The table sorts out which materials, processes and uses are central, as far as the company's own materials confirm.
| Material / use | Role at Acuitas | Primary sources found | Type |
|---|---|---|---|
| LNPs built on designed ionizable and PEG-lipids | Central. The chemistry team says it has designed and synthesized more than 1,000 novel lipids; the ionizable lipid, it says, determines in vivo performance | Website (LNP technology, Capabilities) | Sourced (company's description) |
| Supply of cGMP-grade lipids | Central. It says it manages the development and external production of cGMP-grade proprietary lipids to support partner clinical programs. The names of the manufacturers were not found | Website (Capabilities, Advantage) | Sourced (company's description) |
| Targeted LNP and extrahepatic delivery | In development. LNPs carrying DARPins (engineered proteins) to target immune cells, and local delivery to the lung and eye. Results are conference presentations; whether they are peer-reviewed is unclear | Press release (May 2026), website | Sourced (company's description) |
| RNA design and small-batch GMP production | In January 2026 it acquired a majority stake in the RNA design and manufacturing company RNA Technologies & Therapeutics (amount not disclosed) | Press release (January 2026) | Sourced |
| Drugs of its own | None. "We do not have our own drug development programs" | Corporate presentation (June 2026), website | Sourced (company's description) |
4. Company scale
Acuitas is not listed and does not publish revenue, profit, headcount or financing amounts (the corporate presentation does not either). What can be confirmed from outside is the numbers the company gives about itself and fragments in counterparties' disclosures.
| Item | Content | Type |
|---|---|---|
| Numbers the company gives | Technology in approved products: 2 / clinical trials started by partners in the last three years: 33 / contributions to more than 40 peer-reviewed publications in the last two years (website). An older passage gives 26 trials for 2023-2024 (Advantage page); the counting periods are not the same | Sourced (company's claim) |
| Amounts in counterparties' disclosures | BioNTech pays up to about $1.6-2.45 million in development milestones, $2.5-3.75 million in regulatory milestones and $2.5-3.75 million in commercial milestones, plus tiered low single-digit royalties on net sales (April 2020 agreement, Form 20-F). Arbutus booked $406 thousand of revenue attributed to Acuitas in H1 2026 ($1,095 thousand a year earlier) | Sourced |
| Ownership | Not disclosed. Thomas Madden, a founder, is CEO. No holding company or investor was found | Not yet confirmed |
| Headcount | Not disclosed. The website announces it was named one of Canada's Top Small and Medium Employers for the third year running (April 2026) but gives no headcount | Not disclosed |
"Used in two approved products" and "33 partner clinical trials" are both the company's own numbers, with no third-party confirmation. And the Acuitas-attributed amount in Arbutus's revenue is part of a royalty tied to ONPATTRO sales and does not show Acuitas's revenue or earning power. This article does not estimate Acuitas's size from public materials Not yet confirmed.
5. Resources committed to nanotechnology
The table sorts out, for people, money, outside ties and universities, what was and was not confirmed.
| Item | What was confirmed | Type |
|---|---|---|
| People (R&D sites and headcount) | Based in Vancouver (6190 Agronomy Road). Headcount is not disclosed. The website lists chemistry, formulation, analytical, preclinical, process development and technology transfer, business development and alliance management teams, saying chemistry has designed over 1,000 lipids and formulation makes thousands of formulations a year | Sourced (company's description) / not disclosed |
| Money (R&D spending and capex) | Not disclosed. Manufacturing is outsourced; the company says it uses a "global network of contract manufacturing organizations." No investment in plants was found | Not disclosed / not found (capex) |
| Equity, acquisitions, JVs and divestments | On 8 January 2026 it acquired a majority stake in RNA Technologies & Therapeutics (founded in Montreal in 2022). The two companies continue to operate independently; the amount is not disclosed. No other investment or acquisition was found | Sourced / not found (others) |
| Universities, institutes and public funds | The founders were university researchers, and in 2009 a sponsored research agreement was signed with Alnylam and the University of British Columbia (Alnylam's 10-K exhibit index). Current collaborations appear in the website's papers and announcements (for example with the University of Pennsylvania and Children's Hospital of Philadelphia). No amount of public funding was found | Sourced / not found (public funding) |
Status of main technology and facilities
| Technology / facility | Stage | Date | What the source says (company's description) |
|---|---|---|---|
| LNP in approved products | Approved and marketed | Checked October 2026 | ONPATTRO and COMIRNATY (company's claim; it says COMIRNATY has protected "billions of people in more than 180 countries") |
| Next-generation ionizable lipids (IM and IV) | Preclinical to clinical (some cGMP-ready) | June 2026 | Two lines, intramuscular (vaccines) and intravenous (gene editing), shown relative to a benchmark lipid (ALC-0315); the graph values cannot be read |
| PFV (pre-formed vesicle) manufacturing | In development | July 2025 and June 2026 | Empty LNP and mRNA in a two-vial kit mixed at point of care. The company says potency equals the conventional method (conditions not given), with 2-8 °C long-term storage and potential for room temperature |
6. Track record
| When | Event | Meaning |
|---|---|---|
| 2009 | Founded by Drs. Madden, Hope and Cullis (website). On 27 July, a sponsored research agreement with Alnylam and UBC (then named AlCana Technologies) | University LNP research becomes a company |
| 2012 | On 12 November, a settlement agreement with Arbutus (then Tekmira) and Alnylam. A license agreement followed, under which Arbutus receives 0.75-1.125% of ONPATTRO net sales (Arbutus's 10-K) | Settling an earlier dispute with Arbutus |
| 2018 | ONPATTRO was approved in the US and EU (Q3 2018 per Arbutus). Acuitas says its LNP enabled the product | Both Acuitas and Arbutus describe it as their technology |
| 2020 | On 7 April a non-exclusive license with BioNTech, covering the SARS-CoV-2 surface glycoprotein; BioNTech has an option to convert it to an exclusive license | License relating to the COMIRNATY lipids |
| 2022-2024 | Filed a declaratory judgment suit against Arbutus and Genevant in New York on 18 March 2022, withdrew it in August 2023 and refiled in New Jersey on 4 August. Dismissed without prejudice for lack of jurisdiction on 20 May 2024 | Did not reach the merits (validity or infringement) |
| 2024-2025 | On 12 July 2024 it filed in Delaware a declaratory judgment action seeking to add Acuitas employees as co-inventors on Alnylam's patents. On 1 July 2025 it was dismissed without prejudice for failure to plead facts sufficient to establish standing (Alnylam's 10-K) | Acuitas's position has not been ruled on by a court |
| 2025-2026 | In 2025 it announced a contribution to a personalized CRISPR therapy at a partner hospital (CHOP). On 8 January 2026 it acquired a majority stake in RNA Technologies & Therapeutics. On 18 March it announced its contribution to the publication of AstraZeneca's Phase I study. In May it presented work on targeted LNP and lipid impurities at ASGCT. In June it released a corporate presentation | Widening into RNA design and lipid quality |
7. Plans
in vivo CAR-T and moreThe presentation shows counts of partner products in the clinic (the figures cannot be read); progress depends on partners
mixed at point of careA method in development (company's description); clinical use was not found
from RNA T&T but linkedIntent to offer LNP together with RNA design and small-batch manufacture (January 2026 press release)
is pending (Acuitas is not a party)Acuitas's next steps are not stated in public materials
The company says it is advancing next-generation LNP toward "targeted LNP for extrahepatic therapies such as in vivo CAR T-cells, epigenetic medicines, multivalent vaccines and oncology vaccines" (company's description) Not yet confirmed. Individual partners' development plans and the company's own revenue or funding targets are not in public materials.
None of the following appears in the primary sources Not yet confirmed.
Revenue, profit and headcount / financing or listing plans / expansion of manufacturing / the terms of contracts with individual partners (other than BioNTech) / the terms of any supply agreement for the ONPATTRO or COMIRNATY lipids / whether the co-inventorship action against Alnylam will be refiled / prospects for new approved products.
8. What the company is aiming for in nanotechnology
This section includes points the company does not state directly. They are written as inferences within what the primary sources allow, with their basis.
| What can be read | Primary-source basis | Type |
|---|---|---|
| It intends to stay a provider of LNP "parts and recipes" with no drugs of its own | Corporate presentation: "We do not have our own drug development programs." Website: works in collaboration with partners | Sourced (company policy) |
| It is widening what it offers from lipids to RNA design and manufacture | January 2026 press release: majority stake in RNA T&T; "an integrated approach to these two key components derisks clinical programs" (company's description) | Sourced (company policy) |
| It seeks to differentiate on quality through control of lipid raw-material purity | May 2026 press release: study of aldehyde impurities and RNA-lipid adducts, saying it can "set targets for our approved lipid manufacturers." The EMA assessment report also refers to lipid-related impurities | Inference |
| It treats customers being able to use the technology free of third-party patent threats as a premise of its business | Acuitas's complaint (August 2023): it is "vital to Acuitas's business that its partners ... can use the licensed Acuitas LNP technology free and clear of interference by threats of suit arising from third party patents" (Acuitas's allegation) | Sourced (Acuitas's allegation) |
The basis for "it differentiates on lipid raw-material purity" is the content of the May 2026 press release. The research presented at ASGCT says that impurities such as aldehydes in ionizable lipids bind mRNA to form "adducts" that inhibit translation, and in mice higher adduct levels corresponded to lower IgG expression. The company recommends screening incoming raw materials for aldehyde content and says it has put in place analytical methods (ion-pairing reversed-phase chromatography and LC-MS).
However, this is the company's announcement; the detailed data (dose, numbers, lipid types) and whether it was peer-reviewed cannot be confirmed. This article does not say that Acuitas is better than others or that others' lipids have the same problem Not yet confirmed.
9. Partnership map for nanotechnology
The pattern is that many customers are payload holders, and there are many patent disputes at the edges. Acuitas and Arbutus each describe ONPATTRO's LNP as an application of their own technology, and Arbutus receives a royalty tied to Acuitas. None of the disputes has reached the merits (the one against Arbutus and Genevant was dismissed for lack of jurisdiction and the one against Alnylam for failure to plead standing, both without prejudice). What Acuitas argued is recorded in the court documents and the 10-Ks, but Acuitas's own latest view could not be confirmed for this article. Sourced
10. Technologies, products and services
The following draws on the company's website, corporate presentation and press releases. Research figures are the company's announcements, and animal results cannot be applied directly to humans. This article does not assess the efficacy or safety of any medicine or vaccine. Sourced
| Item | Content (company's description) |
|---|---|
| LNP technology | Nucleic acids are enclosed by ionizable lipids and PEG-lipids (which stabilize the particle). After administration the PEG-lipid is shed, apolipoprotein E (ApoE) binds, cellular receptors recognize the particle and take it up, and the nucleic acid is released from the endosome into the cytoplasm. Payloads include mRNA, siRNA, DNA and guide RNA |
| Lipid design | An iterative loop of design, synthesis, formulation and preclinical characterization using a structure-activity relationship (SAR) model. The company says "ALC-315" is a US registered trademark |
| Services offered | Chemistry, formulation development, analytics, preclinical (with an emphasis on non-human primates), process development and technology transfer, business development and alliance management. The sequence is optional technology evaluation agreement, term sheet, development and option agreement, then license |
| Targeted LNP (ASGCT 2026) | Extended-circulation LNP carrying DARPins (with Athebio) delivering CD20 CAR mRNA to CD8-positive T cells. In mice, plasma half-life rose from 15 minutes to 2 hours and liver expression fell about 10-fold; in non-human primates, over 60% of circulating CD8 T cells expressed the CAR and B cells were depleted at doses as low as 0.25 mg/kg (company's conference presentation) |
| Applications | Infectious disease vaccines (influenza, RSV, shingles, malaria, HIV and others), cancer vaccines, gene editing and modulation, and therapeutic proteins such as mRNA-encoded antibodies (website) |
| Patents in its name (examples) | US 10,166,298 B2 (priority 28 October 2015) and US 10,221,127 B2 (priority 29 June 2015), both titled "Lipids and lipid nanoparticle formulations for delivery of nucleic acids." The claims were not reviewed for this article |
(1) A concrete route by which impurities reduce performance is shown. In the company's announcement, aldehydes, which are process impurities or degradation products of ionizable lipids, bind mRNA chemically to form "RNA-lipid adducts" that inhibit translation. They are often missed by ordinary mRNA purity assays, and the amount depends strongly on time, temperature and the impurity profile of the lipid lot. It is a materials question of what to put in a lipid specification (company announcement; mouse results, which may not apply to other lipids).
(2) Regulators have also referred to lipid impurities. The EMA assessment report adopted for Comirnaty in February 2021 lists two novel lipid excipients (ALC-0315 and ALC-0159) and says that "lipid related impurities have been observed in some recently manufactured finished product batches, correlated with ALC-0315 lipid batches," asking for more information on the synthetic process and control strategy. It does not name any supplier and does not say the lipid is Acuitas's. It also reflects the assessment of that time and does not indicate the quality of the current product.
(3) By mass, the ionizable lipid is more than half of the four lipids. The US prescribing information (DailyMed, 2026-2027 Formula) lists the lipids in one 0.3 mL dose of COMIRNATY as 0.43 mg ionizable lipid, 0.05 mg PEG-lipid, 0.09 mg DSPC and 0.19 mg cholesterol. As shares of the 0.76 mg total by mass: ionizable lipid about 56.6%, PEG-lipid about 6.6%, DSPC about 11.8% and cholesterol about 25.0% Our calculation. This is background for reading that the purity of the most abundant lipid is likely to matter most to product quality (mass, not molar, ratios; our commentary). For the general makeup of LNPs, see our explainer on lipid nanoparticles.
(4) PFV moves where the mixing step happens. Usually mRNA and LNP are combined into particles at the factory. The company's PFV delivers empty LNP and mRNA in separate vials to be mixed where used. That simplifies manufacturing but shifts control of particle size, encapsulation and stability after mixing to the point of use. The company says potency equals the conventional method, but the test conditions are not public.
None of this judges whether any patent is valid or whether any product falls within a patent's scope.
11. Risks
| Risk | Content | Type |
|---|---|---|
| No visibility into finances | Not listed; revenue, profit, funding and headcount are undisclosed. The company's numbers (2 products, 33 trials) are its own claims, with no third-party confirmation | Not yet confirmed |
| Customers' patent risk reaches the business | Arbutus and Genevant sued Pfizer/BioNTech, and Acuitas alleged in its complaint that the suit identifies Acuitas's lipids and LNP. The case is pending and no ruling has been made. BioNTech says it has strong defenses and the outcome is substantially uncertain | Sourced |
| Its own positions have not been ruled on by a court | The declaratory judgment suit against Arbutus and Genevant was dismissed for lack of jurisdiction and the co-inventorship action against Alnylam for failure to plead standing, both without prejudice. The merits are undecided and refiling is not excluded | Sourced |
| Change in demand for ONPATTRO | Arbutus's 10-K expects ONPATTRO sales, and the royalties via Alnylam and Acuitas, to fall as Alnylam's next-generation AMVUTTRA replaces it (a statement about Arbutus's revenue; it does not address Acuitas's revenue directly) | Sourced |
| Reliance on lipid raw-material quality and external manufacturing | cGMP lipids are produced externally, and the company itself shows that impurities such as aldehydes can affect product performance. The EMA report also refers to lipid-related impurities (supplier not identified) | Sourced |
| Competing delivery technologies | Others, such as Genevant, provide different LNP technology (BioNTech licenses from both Acuitas and Genevant). Customers can use more than one technology | Inference |
| Partners' development outcomes | Income depends on partners' development, approval and sales (milestones and royalties are confirmable only to the extent of BioNTech's Form 20-F). This article does not assess partners' trial progress or results | Not yet confirmed |
12. Glossary
- LNP (lipid nanoparticle)
- A particle of lipids that encloses and carries nucleic acids (mRNA, siRNA). See our explainer on lipid nanoparticles.
- PEG-lipid
- A lipid carrying polyethylene glycol; it stabilizes the particle and is shed after administration.
- ApoE (apolipoprotein E)
- A blood protein; the company says that when it binds an LNP, cellular receptors recognize and take up the particle.
- DARPin
- An engineered binding protein (antibody-like) attached to an LNP to target particular cells.
- RNA-lipid adduct
- An undesired compound formed when a lipid impurity such as an aldehyde binds mRNA; it inhibits translation.
- PFV (pre-formed vesicle)
- An empty LNP made before mRNA is loaded; used in a method where it is mixed with mRNA at the point of use.
- Declaratory judgment action
- A suit asking a court to declare non-infringement or invalidity without waiting to be sued; the court examines whether there is an actual controversy.
- Co-inventor
- A claim that a person who contributed to an invention should be named as an inventor; if accepted, rights in the patent may change.
- cGMP
- Current Good Manufacturing Practice, the standard for pharmaceutical manufacture and quality control.
13. References
- Acuitas Therapeutics Official website home page. Company description, the model of having no drugs of its own, two approved products, number of partners' clinical trials (company's statements). https://acuitastx.com/
- Acuitas Therapeutics Official website, "About Us". Founders in 2009, a Vancouver-based company, partner-centric business model. https://acuitastx.com/about-us/
- Acuitas Therapeutics Official website, "The Acuitas Advantage". The model of not developing drugs itself, cGMP-grade lipids, intellectual property approach. https://acuitastx.com/acuitas-advantage/
- Acuitas Therapeutics Official website, "Our LNP Technology". LNP makeup (ionizable lipids and PEG-lipids), ApoE-mediated uptake, extrahepatic delivery. https://acuitastx.com/lnp-technology/
- Acuitas Therapeutics Official website, "Our Capabilities". Descriptions of the chemistry, formulation, analytical, preclinical, process development and technology transfer teams. https://acuitastx.com/capabilities/
- Acuitas Therapeutics Official website, "Our Clinical Applications". Vaccines, gene editing and modulation, therapeutic proteins. https://acuitastx.com/applications/
- Acuitas Therapeutics Official website, "Contact". Address (Vancouver). https://acuitastx.com/contact/
- Acuitas Therapeutics Official website, "Our Team". Senior leadership (CEO, President and CLO, CSO and others). https://acuitastx.com/about-us/team/
- Acuitas Therapeutics Corporate presentation "Non-Confidential Presentation" (June 2026). Business model, partners' announcements, lipid design workflow, the ALC-315 trademark, PFV. https://acuitastx.com/wp-content/uploads/2026/05/Acuitas-Corporate-Presentation.pdf
- Acuitas Therapeutics Press release (8 January 2026). Acquisition of a majority stake in RNA Technologies & Therapeutics. https://acuitastx.com/wp-content/uploads/2026/01/20260108-Acuitas-RNA-TT-Strategic-Investment-Press-Release-.pdf
- Acuitas Therapeutics Press release (20 May 2026). ASGCT 2026 presentations: targeted LNP; lipid impurities (aldehydes) and RNA-lipid adducts. https://acuitastx.com/wp-content/uploads/2026/05/2026-ASGCT-Post-Conference-Press-Release.pdf
- Acuitas Therapeutics Press release (18 March 2026). Publication of AstraZeneca's Phase I study and Acuitas's contribution of the LNP. https://acuitastx.com/wp-content/uploads/2026/03/Acuitas-Therapeutics-Lipid-Nanoparticle-Technology-Supports-Positive-Phase-I-Data-Published-by-AstraZeneca-Press-Release.pdf
- BioNTech Annual Report on Form 20-F for the year ended 31 December 2025 (filed 10 March 2026). Terms of the non-exclusive license from Acuitas (April 2020); defendant's description of the Arbutus/Genevant proceeding. https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm
- Alnylam Pharmaceuticals Annual Report on Form 10-K for the year ended 31 December 2025 (filed 12 February 2026). Acuitas's declaratory judgment action on co-inventorship (filed July 2024, dismissed July 2025) and the index of past agreements with Acuitas. https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm
- Arbutus Biopharma Annual Report on Form 10-K for the year ended 31 December 2025 (filed 23 March 2026). The royalty arising from the settlement and license with Acuitas (0.75-1.125%); ONPATTRO. https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm
- Arbutus Biopharma Quarterly Report on Form 10-Q for the quarter ended 30 June 2026 (filed 12 August 2026). Revenue attributed to Acuitas ($406 thousand in H1 2026). https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/abus-20260630.htm
- U.S. District Court for the District of New Jersey Acuitas Therapeutics Inc. v. Genevant Sciences GmbH, No. 3:23-cv-4200, ECF 35, Opinion (20 May 2024). https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0_1.pdf
- U.S. District Court for the District of New Jersey (Acuitas's complaint) Same case, ECF 1 (4 August 2023). Acuitas's complaint, containing Acuitas's own allegations (it supplies the LNP and lipids in Comirnaty; its business model). https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.1.0.pdf
- U.S. National Library of Medicine (DailyMed) COMIRNATY (2026-2027 Formula) prescribing information (SPL, published 7 September 2026). Lipid masses per 0.3 mL dose. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48c86164-de07-4041-b9dc-f2b5744714e5
- European Medicines Agency (EMA) Assessment report for Comirnaty, EMA/707383/2020 (adopted 19 February 2021; corrected October 2023). The two novel lipid excipients and the statement on lipid-related impurities. https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf
- Google Patents US 10,166,298 B2, "Lipids and lipid nanoparticle formulations for delivery of nucleic acids" (original assignee Acuitas Therapeutics; priority 28 October 2015; issued 1 January 2019). https://patents.google.com/patent/US10166298B2/en
- Google Patents US 10,221,127 B2, "Lipids and lipid nanoparticle formulations for delivery of nucleic acids" (original assignee Acuitas Therapeutics; priority 29 June 2015; issued 5 March 2019). https://patents.google.com/patent/US10221127B2/en
14. Claim-to-source audit
| Claim in the text | Type | Source |
|---|---|---|
| Company overview: not listed, Vancouver, founded in 2009 by Madden, Hope and Cullis, partner-centric model, no drug development of its own, two approved products, 33 partner clinical trials, more than 40 publications, contribution to a personalized CRISPR therapy (2025) | Sourced (company's claim) | References 1, 2, 3, 9 https://acuitastx.com/ https://acuitastx.com/about-us/ https://acuitastx.com/acuitas-advantage/ https://acuitastx.com/wp-content/uploads/2026/05/Acuitas-Corporate-Presentation.pdf |
| Address (6190 Agronomy Road, Suite 205) and leadership (CEO Thomas Madden, President and CLO Miranda Lam, CSO Ying Tam, VP Christopher Barbosa, VP Sean Semple) | Sourced | References 7, 8 https://acuitastx.com/contact/ https://acuitastx.com/about-us/team/ |
| The description of LNP makeup and action (ionizable and PEG-lipids, ApoE, endosomal release, payloads, extrahepatic delivery) and applications | Sourced (company's claim) | References 4, 6 https://acuitastx.com/lnp-technology/ https://acuitastx.com/applications/ |
| Team functions and figures (chemistry over 1,000 lipids, formulation thousands of formulations a year, preclinical with non-human primates, a global network of CMOs, external cGMP lipid production) | Sourced (company's claim) | References 5, 3 https://acuitastx.com/capabilities/ https://acuitastx.com/acuitas-advantage/ |
| Corporate presentation (June 2026): the list of partners' announcements (Beam, Precision BioSciences, CureVac, Tune, Arbor, CREATE, Metagenomi, Centivax, nChroma, Ukko, Scribe), the ALC-315 trademark, the lipid design loop, PFV, the collaboration steps | Sourced (company's claim) | Reference 9 https://acuitastx.com/wp-content/uploads/2026/05/Acuitas-Corporate-Presentation.pdf |
| The BioNTech license (April 2020; non-exclusive; SARS-CoV-2 surface glycoprotein; milestone ranges; low single-digit royalty; option to go exclusive), and BioNTech's licenses of patent filings from both Acuitas and Genevant | Sourced | Reference 13 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| The royalty Arbutus receives from the settlement and license with Acuitas (0.75-1.125%), revenue attributed to Acuitas (H1 2026 $406 thousand; $1,095 thousand a year earlier), and the expected decline in ONPATTRO sales | Sourced | References 15, 16 https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/abus-20260630.htm |
| Alnylam's 10-K: the former name AlCana Technologies, the sponsored research agreement of 27 July 2009, the settlement agreement of 12 November 2012, the 12 July 2024 declaratory judgment action (co-inventors) and its dismissal without prejudice on 1 July 2025 | Sourced | Reference 14 https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm |
| The District of New Jersey opinion: Acuitas's claim (that Comirnaty does not infringe Arbutus's patents), the March 2022 New York suit and its August 2023 withdrawal and refiling, and the 20 May 2024 dismissal without prejudice for lack of jurisdiction | Sourced | Reference 17 https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0_1.pdf |
| Acuitas's complaint: it supplies and licenses the LNP and lipids in Comirnaty, and it is vital that partners can use the technology free of third-party patent interference (Acuitas's allegations) | Sourced (company's claim) | References 18, 17 https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.1.0.pdf https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0_1.pdf |
| Majority stake in RNA Technologies & Therapeutics (8 January 2026; founded in Montreal in 2022; amount not disclosed) | Sourced | Reference 10 https://acuitastx.com/wp-content/uploads/2026/01/20260108-Acuitas-RNA-TT-Strategic-Investment-Press-Release-.pdf |
| ASGCT 2026 presentations: targeted LNP (15 minutes to 2 hours, about 1/10, over 60%, 0.25 mg/kg), aldehyde impurities and RNA-lipid adducts, analytical methods | Sourced (company's claim) | Reference 11 https://acuitastx.com/wp-content/uploads/2026/05/2026-ASGCT-Post-Conference-Press-Release.pdf |
| Publication of AstraZeneca's Phase I study and Acuitas's provision of the LNP (18 March 2026) | Sourced (company's claim) | Reference 12 https://acuitastx.com/wp-content/uploads/2026/03/Acuitas-Therapeutics-Lipid-Nanoparticle-Technology-Supports-Positive-Phase-I-Data-Published-by-AstraZeneca-Press-Release.pdf |
| Lipid masses in one 0.3 mL dose of COMIRNATY (0.43 / 0.05 / 0.09 / 0.19 mg; 2026-2027 Formula) | Sourced | Reference 19 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48c86164-de07-4041-b9dc-f2b5744714e5 |
| The EMA assessment report: the two novel lipid excipients (ALC-0315 and ALC-0159) and the statement on lipid-related impurities correlated with ALC-0315 lots (adopted February 2021) | Sourced | Reference 20 https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf |
| Titles, priority dates and issue dates of patents in its name (US 10,166,298 B2 and US 10,221,127 B2) | Sourced | References 21, 22 https://patents.google.com/patent/US10166298B2/en https://patents.google.com/patent/US10221127B2/en |
| The logo image is the logo image published on the official website, with only the margin trimmed | Sourced | Reference 1 https://acuitastx.com/ |
| Revenue, profit, headcount and financing, the names of manufacturers, the supply relationship for the lipids in the Pfizer/BioNTech vaccine, contract terms with individual partners (other than BioNTech), the amount of public funding, and refiling of the action against Alnylam | Not yet confirmed | Not in official materials; this article does not assert they do not exist (this article) |
| The readings "it stays a provider with no drugs," "it is widening from lipids to RNA design and manufacture," "it differentiates on lipid purity control" and "customers using the technology free of patent threats is a premise of its business" | Inference | References 9, 10, 11, 20, 18 https://acuitastx.com/wp-content/uploads/2026/05/Acuitas-Corporate-Presentation.pdf https://acuitastx.com/wp-content/uploads/2026/01/20260108-Acuitas-RNA-TT-Strategic-Investment-Press-Release-.pdf https://acuitastx.com/wp-content/uploads/2026/05/2026-ASGCT-Post-Conference-Press-Release.pdf https://www.ema.europa.eu/en/documents/assessment-report/comirnaty-epar-public-assessment-report_en.pdf https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.1.0.pdf |
| Classifying Acuitas as "nanomedicine," the four-type scheme, the mass shares of the COMIRNATY lipids (0.43 / 0.76 = about 56.6%, etc.) and the commentary in the materials-engineer section | Our calculation | Our own organization and calculation (see our technical explainers for general technology background) |
Last updated: 9 October 2026 / Troy Technical
This article is based on Acuitas's website, press releases and corporate presentation, BioNTech's Form 20-F, the 10-Ks and 10-Q of Alnylam and Arbutus, District of New Jersey documents, a US prescribing information, an EMA assessment report and patent publications. It uses no market-research estimates or press-based figures. Because Acuitas is not listed, its financials are not published, and this article does not estimate them. Figures the company gives (involvement in approved products, partners' trial counts, conference results) are treated as the company's claims or announcements and have not been verified by third parties. Patent disputes are treated as each party's position, and this article does not judge whether any patent is valid or infringed. Items marked "Inference" are our reading of the primary sources and are not company disclosures. This article does not advise individual readers on the efficacy or safety of any medicine or vaccine, or on investment.